Repligen vs Bio-Techne

Repligen (RGEN), health care, and Bio-Techne (TECH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Bio-Techne is worth $11.4B on the stock market and Repligen $10.4B: Bio-Techne is valued at 10% more. Repligen's operating margin in its latest fiscal year was 7.47% and Bio-Techne's 20.7%. Over the past year Repligen's share price has moved +6.35% and Bio-Techne's +25.2%.

Key facts

Repligen market value
$10.4B
Bio-Techne market value
$11.4B
Bio-Techne P/E
66.6
Repligen revenue
$738.3MFY to 2025-12-31
Bio-Techne revenue
$1.2BFY to 2026-06-30
Superinvestors holding both
2

Market values as of .

Repligen vs Bio-Techne: every measure side by side
Measure Repligen Bio-Techne
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312026-06-30
Size
Market cap$10.4Blower$11.4Bhigher
Revenue$738.3Mlower$1.2Bhigher
Earnings$48.9Mlower$181.9Mhigher
Employees2,000lower3,000higher
Total assets$2.9Bhigher$2.6Blower
Valuation
P/E—66.6
P/S14.1higher9.4lower
P/B4.4lower5.3higher
Dividend yield0.00%lower0.33%higher
Profitability
Operating margin7.47%lower20.7%higher
Balance sheet
Net assets$2.1Blower$2.1Bhigher
Total liabilities$843.6Mhigher$478.5Mlower
Total debt$542.2Mhigher$200Mlower
Cash on hand$566Mhigher$264.7Mlower
Price change
Today-0.24%lower-0.23%higher
1 year+6.35%lower+25.2%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Repligen / Bio-Techne). Who owns RGEN · Who owns TECH

Further comparisons

Learn

Questions and answers

Which is bigger, Repligen or Bio-Techne?

By market value, Bio-Techne is the larger: $11.4B against $10.4B for Repligen. By revenue in its latest fiscal year, Bio-Techne is the larger: $1.2B against $738.3M for Repligen.

Which has the higher operating margin?

Bio-Techne: 20.7%, against 7.47% for Repligen. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Bio-Techne: 0.33%, against 0.00% for Repligen. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Repligen: $542.2M, against $200M for Bio-Techne. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Repligen and Bio-Techne?

In their latest 13F filings, Lee Ainslie and Wallace Weitz hold both.

Cite this page

Funkfolio, “Repligen vs Bio-Techne”, data as of 17 November 2026. https://funkfolio.com/compare/rgen-vs-tech

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.